AACR 2019: Savolitinib Plus Osimertinib in EGFR -Mutant, MET-Amplified NSCLC
Posted: Wednesday, April 24, 2019
The combination of the investigational MET inhibitor savolitinib and the EGFR inhibitor osimertinib produced clinical responses in some patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had developed resistance to prior EGFR-targeted therapies through MET-gene amplification. These interim results were from two expansion cohorts of a phase Ib clinical trial that were presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta (Abstract CT033) and published in Cancer Discovery.
In patients with this type of EGFR mutation, “data from the TATTON trial demonstrate for the first time the benefit of adding a MET inhibitor to an EGFR inhibitor,” stated Lecia V. Sequist, MD, MPH, of the Massachusetts General Hospital Cancer Center, Boston, in an AACR press release. “The study has shown efficacy of combination targeted therapy in a patient population for whom chemotherapy is the current primary treatment option.”
All patients received osimertinib at 80 mg daily plus savolitinib at 600 mg daily. The first cohort (n = 46) of patients had received prior first- or second-generation EGFR tyrosine kinase inhibitors (TKIs), whereas patients in the second cohort (n = 48) had previously received a third-generation EGFR TKI. Therapy with osimertinib and savolitinib yielded an objective response rate of 52% and 28%; 24 and 12 partial responses; and a median duration of response of 7.1 and 9.7 months in the 2 cohorts, respectively.
Most patients (90%) experienced at least a single treatment-related adverse event, including nausea (52%), vomiting (38%), diarrhea (27%), and fatigue (25%). Serious adverse events were reported in 29% of patients. A phase II study, SAVANNAH, is currently underway to study osimertinib plus savolitinib in patients with EGFR-mutant, MET-amplified NSCLC who have experienced disease progression with osimertinib.
Disclosure: The study authors’ disclosure information may be found at abstractsonline.com.
